ロード中...
Efficacy of dasatinib for the treatment of intractable chronic myeloid leukemia
Dasatinib (DAS) is a well tolerated oral dual SRC inhibitor with remarkable activity against all phases of imatinib-resistant chronic myeloid leukemia (CML). This paper focuses on the activity of DAS in intractable CML, and reviews outcomes of patients enrolled on DAS clinical trials. Safety and tol...
保存先:
| 主要な著者: | , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Dove Medical Press
2010
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3262317/ https://ncbi.nlm.nih.gov/pubmed/22282699 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/JBM.S7158 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|